New insider activity at Privia Health Group ( (PRVA) ) has taken place on May 3, 2025.
In recent transactions involving Privia Health Group stock, key executives have made significant sales. Director Matthew Shawn Morris sold 10,309 shares, amounting to $240,508. CEO Parth Mehrotra parted with 15,100 shares, totaling $352,283. Meanwhile, EVP & CFO David Mountcastle sold 3,445 shares, valued at $80,371.
Recent Updates on PRVA stock
Recent developments for Privia Health Group’s stock include several changes in price targets by different analysts. Baird raised its price target due to a cautious outlook on policy overhangs and potential macroeconomic headwinds, suggesting companies will maintain conservative guidance. Truist lowered its price target, citing broader market uncertainty and potential impacts from tariffs on related sectors like hospitals and pharmaceuticals, which could affect investment decisions. Barclays increased its price target in anticipation of Q1 earnings in the managed care space. Additionally, Privia Health announced a partnership with Integrated Medical Services in Arizona, expected to be profitable by late 2025, which may have influenced some of these target adjustments.
Spark’s Take on PRVA Stock
According to Spark, TipRanks’ AI Analyst, PRVA is a Outperform.
Privia Health Group demonstrates solid financial and operational performance with strong growth prospects, as highlighted in their earnings call. However, technical analysis indicates mixed signals, and the high P/E ratio suggests overvaluation risks. Despite these concerns, the company’s robust financial position and growth expectations lead to a favorable score.
To see Spark’s full report on PRVA stock, click here.
More about Privia Health Group
YTD Price Performance: 16.60%
Average Trading Volume: 821,943
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.78B